APA (7th ed.) Citation

Jorgenson, M. R., Kleiboeker, H., Garg, N., Parajuli, S., Mandelbrot, D. A., Odorico, J. S., . . . Smith, J. A. (2022). Letermovir conversion after valganciclovir treatment in cytomegalovirus high‐risk abdominal solid organ transplant recipients may promote development of cytomegalovirus‐specific cell mediated immunity. Transplant Infectious Disease, 24(1), 1. https://doi.org/10.1111/tid.13766

Chicago Style (17th ed.) Citation

Jorgenson, Margaret R., Hanna Kleiboeker, Neetika Garg, Sandesh Parajuli, Didier A. Mandelbrot, Jon S. Odorico, Christopher M. Saddler, and Jeannina A. Smith. "Letermovir Conversion After Valganciclovir Treatment in Cytomegalovirus High‐risk Abdominal Solid Organ Transplant Recipients May Promote Development of Cytomegalovirus‐specific Cell Mediated Immunity." Transplant Infectious Disease 24, no. 1 (2022): 1. https://doi.org/10.1111/tid.13766.

MLA (9th ed.) Citation

Jorgenson, Margaret R., et al. "Letermovir Conversion After Valganciclovir Treatment in Cytomegalovirus High‐risk Abdominal Solid Organ Transplant Recipients May Promote Development of Cytomegalovirus‐specific Cell Mediated Immunity." Transplant Infectious Disease, vol. 24, no. 1, 2022, p. 1, https://doi.org/10.1111/tid.13766.